[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Correale P, Micheli L, Vecchio MT, Sabatino M, Petrioli R, Pozzessere D, Marsili S, Giorgi G, Lozzi L, Neri P, Francini G: A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Br J Cancer; 2001 Nov 30;85(11):1722-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A PTH-rP-derived peptide, designated PTR-4 was identified, which is capable to bind HLA-A2.1 molecules and to generate PTH-rP-specific cytotoxic T cell (CTL) lines from healthy HLA-A2.1(+) individual peripheral-blood-mononuclear-cells (PBMC).
  • In this model, we investigated the in vitro possibility of generating an efficient PTH-rP specific CTL response by cyclical stimulations with IL-2 and PTR-4 peptide-pulsed autologous dendritic cells (DC), of HLA-A2.1(+) tumour infiltrating lymphocytes (TIL) derived from a patient with metastatic prostate carcinoma.
  • A T cell line generated in this way (called TM-PTR-4) had a CD3(+), CD5(+), CD4(-), CD8(+), CD45(Ro+), CD56(-) immunophenotype and a HLA-A2.1 restricted cytotoxic activity to PTR-4-peptide pulsed CIR-A2 (HLA-A2.1(+)) target cells, PTH-rP(+)/HLA-A2.1(+) CIR-A2 transfected with PTH-rP gene, prostate carcinoma LNCaP cells, and autologous metastatic prostate cancer cells (M-CaP).
  • Our results provide evidence that PTR-4 peptide-pulsed autologous DC may break the tolerance of human TIL against the autologous tumour by inducing a PTH-rP-specific CTL immune reaction.
  • In conclusion PTR-4 peptide-pulsed autologous DC may be a promising approach for vaccine-therapy and antigen-specific CTL adoptive immunotherapy of hormone-resistant prostrate cancer.
  • [MeSH-major] Dendritic Cells / immunology. Interleukin-2 / pharmacology. Lymphocytes, Tumor-Infiltrating / immunology. Prostatic Neoplasms / therapy. Proteins / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Bone Neoplasms / immunology. Bone Neoplasms / secondary. Cytotoxicity Tests, Immunologic. Cytotoxicity, Immunologic / drug effects. Cytotoxicity, Immunologic / immunology. Epitopes / immunology. Flow Cytometry. HLA-A2 Antigen / immunology. Humans. Immunophenotyping. Male. Neoplasm Metastasis. Oligopeptides / immunology. Parathyroid Hormone-Related Protein. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2001 Cancer Research Campaign
  • [Cites] Eur J Cancer. 2001 May;37(7):892-902 [11313178.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1690-5 [10415076.001]
  • [Cites] Semin Hematol. 1985 Jan;22(1):27-40 [3155876.001]
  • [Cites] J Immunol Methods. 1987 Aug 24;102(1):127-41 [3305708.001]
  • [Cites] J Immunol. 1989 May 15;142(10):3714-25 [2785562.001]
  • [Cites] J Clin Invest. 1990 Mar;85(3):955-61 [2179270.001]
  • [Cites] Nature. 1990 May 31;345(6274):449-52 [2342577.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6248-55 [2119252.001]
  • [Cites] J Exp Med. 1991 Jan 1;173(1):273-6 [1670640.001]
  • [Cites] Semin Oncol. 1991 Aug;18(4 Suppl 5):11-5 [1925624.001]
  • [Cites] Eur J Cancer. 1991;27(11):1393-5 [1835854.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Cancer Immunol Immunother. 1992;34(4):272-8 [1371427.001]
  • [Cites] Biotherapy. 1992;5(1):47-61 [1389902.001]
  • [Cites] Cancer. 1993 Feb 1;71(3 Suppl):880-6 [8428342.001]
  • [Cites] Cancer Immunol Immunother. 1993 May;36(5):315-22 [8477417.001]
  • [Cites] Br J Cancer. 1993 Jun;67(6):1430-6 [8512828.001]
  • [Cites] J Natl Cancer Inst. 1993 Aug 18;85(16):1294-302 [8340941.001]
  • [Cites] Eur J Immunol. 1993 Sep;23(9):2072-7 [8370389.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66 [8028037.001]
  • [Cites] Cancer Immunol Immunother. 1994 Jul;39(1):15-21 [8044822.001]
  • [Cites] Semin Oncol. 1995 Feb;22(1):74-80 [7855622.001]
  • [Cites] Immunol Today. 1995 Mar;16(3):117-21 [7718082.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6(2):285-90 [7540894.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 5;87(13):982-90 [7629885.001]
  • [Cites] Eur J Immunol. 1995 Sep;25(9):2588-97 [7589131.001]
  • [Cites] J Immunol Methods. 1996 Sep 27;196(2):137-51 [8841452.001]
  • [Cites] Cancer Treat Rev. 1996 Jul;22(4):289-331 [9025785.001]
  • [Cites] J Natl Cancer Inst. 1997 Feb 19;89(4):293-300 [9048833.001]
  • [Cites] Life Sci. 1997;60(23):2035-41 [9180357.001]
  • [Cites] Cell Immunol. 1997 Aug 25;180(1):70-83 [9316641.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1572-80 [9362424.001]
  • [Cites] Cancer Immunol Immunother. 1998 May;46(3):121-7 [9625535.001]
  • [Cites] Prostate. 1998 Jun 15;36(1):39-44 [9650914.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(2):210-3 [9741323.001]
  • [Cites] Ann Oncol. 1999 Jan;10(1):21-7 [10076717.001]
  • [Cites] Adv Immunol. 1999;72:255-324 [10361578.001]
  • [Cites] Scand J Clin Lab Invest Suppl. 1968;97:51-76 [4179067.001]
  • (PMID = 11742494.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epitopes; 0 / HLA-A2 Antigen; 0 / Interleukin-2; 0 / Oligopeptides; 0 / PTHLH protein, human; 0 / Parathyroid Hormone-Related Protein; 0 / Proteins
  • [Other-IDs] NLM/ PMC2363980
  •  go-up   go-down


2. Ishmael FT, Fang X, Galdiero MR, Atasoy U, Rigby WF, Gorospe M, Cheadle C, Stellato C: Role of the RNA-binding protein tristetraprolin in glucocorticoid-mediated gene regulation. J Immunol; 2008 Jun 15;180(12):8342-53
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glucocorticoids (GCs) are the mainstay of anti-inflammatory therapy.
  • Modulation of posttranscriptional regulation (PTR) of gene expression by GCs is a relevant yet poorly characterized mechanism of their action.
  • The RNA-binding protein tristetraprolin (TTP) plays a central role in PTR by binding to AU-rich elements in the 3'-untranslated region of proinflammatory transcripts and accelerating their decay.
  • To investigate the importance of PTR and the role of TTP in GC function, we compared the effect of GC treatment on genome-wide gene expression using mouse embryonic fibroblasts (MEFs) obtained from wild-type and TTP(-/-) mice.
  • These results reveal a strong and previously unrecognized contribution of PTR to the anti-inflammatory action of GCs and point at TTP as a key factor mediating this process through a complex mechanism of action.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):1891-9 [10706852.001]
  • [Cites] Mol Cell Endocrinol. 2007 Sep 15;275(1-2):79-97 [17561338.001]
  • [Cites] Mol Pharmacol. 2007 Oct;72(4):799-809 [17622575.001]
  • [Cites] J Allergy Clin Immunol. 2007 Dec;120(6):1247-63; quiz 1264-5 [18073120.001]
  • [Cites] J Biol Chem. 2008 Apr 25;283(17):11689-99 [18256032.001]
  • [Cites] Physiol Genomics. 2005 Sep 21;23(1):28-45 [15985639.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(3):222-30 [16113438.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(3):239-46 [16113441.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(3):247-54 [16113442.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(3):255-63 [16113443.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1711-23 [16236742.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Jan;34(1):73-82 [16166738.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D111-4 [16381826.001]
  • [Cites] Eur Respir J. 2006 Feb;27(2):413-26 [16452600.001]
  • [Cites] Genes Cells. 2006 Mar;11(3):305-17 [16483318.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):120-30 [16421520.001]
  • [Cites] J Biol Chem. 2006 Mar 24;281(12):8161-8 [16439363.001]
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23456-63 [16787927.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):4141-8 [16951379.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):9126-35 [16982682.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(24):9196-208 [17030620.001]
  • [Cites] Arthritis Res. 2000;2(3):172-4 [11094425.001]
  • [Cites] Gene. 2001 Mar 7;265(1-2):11-23 [11255003.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25236-42 [11309384.001]
  • [Cites] J Biol Chem. 2002 Mar 15;277(11):9606-13 [11782475.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):195-205 [11994740.001]
  • [Cites] Biochem Soc Trans. 2002 Nov;30(Pt 6):945-52 [12440952.001]
  • [Cites] Cytokine. 2002 Nov 7;20(3):91-106 [12453467.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47444-50 [12356755.001]
  • [Cites] Neurochem Res. 2002 Oct;27(10):957-80 [12462398.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48558-64 [12324455.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13928-35 [12578839.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):19947-55 [12639954.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3554-61 [12789264.001]
  • [Cites] Genome Res. 2003 Aug;13(8):1863-72 [12902380.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2129-41 [12952881.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4369-78 [14530362.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2003;75:43-68 [14604009.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):21489-99 [15010466.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):27870-7 [15117938.001]
  • [Cites] EMBO J. 2004 Aug 4;23(15):3092-102 [15257295.001]
  • [Cites] Trends Genet. 2004 Oct;20(10):491-7 [15363903.001]
  • [Cites] Science. 1991 Jul 19;253(5017):312-4 [1857966.001]
  • [Cites] Immunology. 1992 Jan;75(1):189-95 [1537596.001]
  • [Cites] Biochem Pharmacol. 1992 Oct 20;44(8):1569-76 [1417981.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):985-91 [8094998.001]
  • [Cites] Annu Rev Biochem. 1993;62:289-321 [8352591.001]
  • [Cites] Trends Biochem Sci. 1995 Nov;20(11):465-70 [8578590.001]
  • [Cites] Immunity. 1996 May;4(5):445-54 [8630730.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Science. 1998 Aug 14;281(5379):1001-5 [9703499.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15293-8 [9860962.001]
  • [Cites] Arthritis Res Ther. 2004;6(6):248-64 [15535838.001]
  • [Cites] Exp Biol Med (Maywood). 2005 Jan;230(1):75-81 [15618129.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):953-61 [15634918.001]
  • [Cites] J Interferon Cytokine Res. 2005 Jan;25(1):1-10 [15684617.001]
  • [Cites] Biochem Pharmacol. 2005 Mar 1;69(5):733-40 [15710351.001]
  • [Cites] Mol Pharmacol. 2005 Jun;67(6):2148-61 [15778452.001]
  • [Cites] J Allergy Clin Immunol. 2007 Jan;119(1):115-22 [17208592.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Feb;8(2):113-26 [17245413.001]
  • [Cites] Genes Dev. 2007 Mar 15;21(6):719-35 [17369404.001]
  • [Cites] Mediators Inflamm. 2006;2006(6):40691 [17392586.001]
  • [Cites] Semin Immunol. 2000 Feb;12(1):85-98 [10723801.001]
  • (PMID = 18523301.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 AG000511-10; United States / NIAID NIH HHS / AI / R01 AI060990-04; United States / NIAID NIH HHS / AI / R01 AI 060990-01A1; United States / NIAID NIH HHS / AI / AI060990-04; United States / NIAID NIH HHS / AI / R01 AI060990
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / RNA-Binding Proteins; 0 / Tristetraprolin; 51333-22-3 / Budesonide
  • [Other-IDs] NLM/ NIHMS46516; NLM/ PMC2505276
  •  go-up   go-down


3. Patel N, McNutt LA, Lodise TP: Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother; 2008 Aug;52(8):2933-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Contemporary literature lacks a definition of prior antibiotic exposure which captures all patients at risk of developing piperacillin-tazobactam-resistant Pseudomonas aeruginosa (PTR-PA).
  • The results indicated that individual antibiotics that are associated with PTR-PA differ depending on the definition of prior antibiotic exposure utilized.
  • When the specific antibiotic used was replaced by the number of prior exposures, the number of exposures was the only variable associated with an increased risk of antibiotic resistance at each time threshold.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Pseudomonas Infections / drug therapy. Pseudomonas aeruginosa / drug effects. Respiratory Tract Infections / drug therapy
  • [MeSH-minor] Aged. Drug Resistance, Multiple, Bacterial. Female. Humans. Male. Middle Aged. Penicillanic Acid / adverse effects. Penicillanic Acid / analogs & derivatives. Penicillanic Acid / pharmacology. Penicillanic Acid / therapeutic use. Piperacillin / adverse effects. Piperacillin / pharmacology. Piperacillin / therapeutic use. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect. 2007 Nov;55(5):414-8 [17850877.001]
  • [Cites] Infect Control Hosp Epidemiol. 2007 Aug;28(8):959-65 [17620244.001]
  • [Cites] Am J Epidemiol. 2003 May 15;157(10):940-3 [12746247.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38(5):670-7 [14986251.001]
  • [Cites] Arch Pediatr Adolesc Med. 2004 Jun;158(6):556-60 [15184219.001]
  • [Cites] Stat Methods Med Res. 1995 Sep;4(3):197-217 [8548103.001]
  • [Cites] Comput Biomed Res. 1998 Oct;31(5):363-73 [9790741.001]
  • [Cites] Microb Drug Resist. 2005 Spring;11(1):68-74 [15770098.001]
  • [Cites] J Antimicrob Chemother. 2005 Apr;55(4):535-41 [15728150.001]
  • [Cites] Am J Epidemiol. 2005 Aug 1;162(3):199-200 [15987728.001]
  • [Cites] Clin Infect Dis. 2005 Aug 15;41(4):441-9 [16028150.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jun;50(6):2192-6 [16723582.001]
  • [Cites] Infect Control Hosp Epidemiol. 2006 Sep;27(9):893-900 [16941312.001]
  • [Cites] J Antimicrob Chemother. 2006 Nov;58(5):1082-5 [16950822.001]
  • [Cites] Intensive Care Med. 2006 Dec;32(12):1970-8 [16957901.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Feb;51(2):417-22 [17158943.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Dec;23(12):740-7 [12517017.001]
  • (PMID = 18519718.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 157044-21-8 / piperacillin, tazobactam drug combination; 87-53-6 / Penicillanic Acid; X00B0D5O0E / Piperacillin
  • [Other-IDs] NLM/ PMC2493121
  •  go-up   go-down


Advertisement
4. Scarpioni R, Michieletti E, Cristinelli L, Ugolotti U, Scolari F, Venturelli C, Cancarini G, Pecchini P, Malberti F, Maroldi R, Rozzi G, Olivetti L: Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER). J Nephrol; 2005 Jul-Aug;18(4):423-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER).
  • BACKGROUND: Many studies suggest a major prevalence of atherosclerotic renovascular disease (ARVD), caused by mono or bilateral renal artery stenosis (RAS).
  • Unfortunately, there is no definite therapy to cure this disease to date; therefore, ARVD is burdened by important clinical complications with high social and economic costs.
  • The last few years have seen important advancements in both medical therapy and in interventional radiology (for example, percutaneous transluminal renal artery stenting (PTRS)).
  • METHODS: The protocol of a prospective, multicenter, randomized trial "Nephropathy Ischemic Therapy (NITER)" is presented.
  • This study aims to evaluate whether medical therapy plus interventional PTRS is superior to medical therapy alone according to the following combined primary endpoint: death or dialysis initiation or reduction by >20% in estimated GFR after 0.5, 1, and 2 yrs of follow-up and an extended follow-up until the 4th year.
  • Medical therapy means drugs to control hypertension, improve dyslipidemia and optimize platelet anti-aggregant therapy.
  • The sample size is estimated in 50 patients per group to achieve a statistical significance of 0.05 in case of a reduction by 50% in the combined endpoints.
  • [MeSH-major] Atherosclerosis / therapy. Blood Vessel Prosthesis Implantation / instrumentation. Hypolipidemic Agents / therapeutic use. Kidney Failure, Chronic / prevention & control. Platelet Aggregation Inhibitors / therapeutic use. Renal Artery Obstruction / therapy. Stents
  • [MeSH-minor] Aged. Aged, 80 and over. Antihypertensive Agents / therapeutic use. Disease Progression. Drug Therapy, Combination. Follow-Up Studies. Glomerular Filtration Rate / physiology. Humans. Magnetic Resonance Angiography. Prospective Studies. Treatment Outcome. Ultrasonography, Doppler, Duplex

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16245247.001).
  • [ISSN] 1121-8428
  • [Journal-full-title] Journal of nephrology
  • [ISO-abbreviation] J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Hypolipidemic Agents; 0 / Platelet Aggregation Inhibitors
  •  go-up   go-down


5. Díaz R, Aparicio J, Gironés R, Molina J, Palomar L, Segura A, Montalar J: Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer; 2005 Sep;5(3):197-202
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
  • BACKGROUND: The objective of this study was to analyze prognostic factors for survival and to assess the applicability of Kohne's classification in patients treated with irinotecan- or oxaliplatin-based first-line chemotherapy.
  • Primary tumor resection (PTR) was performed in 80.6% of patients who initially had stage IV disease.
  • Chemotherapy consisted of fluoropyrimidines or raltitrexed plus irinotecan (50.5%), oxaliplatin (38.5%), or both (11%).
  • Significantly unfavorable prognostic factors were PTR not being performed, disease involvement of >1 organ, liver metastases, undifferentiated histology, EGOG PS>1, increased serum carcinoembryonic antigen and cancer antigen 19.9 levels, hypoalbuminemia, leucocytosis, and elevated alkaline phosphatase and lactate dehydrogenase (LDH) levels.
  • Only ECOG PS, PTR, increased LDH level, no hypoalbuminemia, and number of organs involved retained prognostic value in the multivariate analysis.
  • For patients with stage IV disease at presentation, PTR was associated with a significantly longer survival, mainly in patients with an ECOG PS of 0/1.
  • CONCLUSION: Eastern Cooperative Oncology Group PS, PTR, serum albumin, increased LDH levels, and organ involvement were the main prognostic indicators in our series.
  • Kohne's prognostic groups, developed in the era of 5-fluorouracil treatment, also seem to be applicable to patients treated with combination chemotherapy.
  • However, the benefit of PTR and multiple-agent chemotherapy is questionable in patients with an ECOG PS of >1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Predictive Value of Tests. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197623.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Tawfiq N, Lakhrib N, Mharech A, Benchakroun N, Benider A, Benkirane A, Zamiati S, Mansouri I, Roubal M, Kadiri Fatmi ME, Elbenna N, Abdelouafi A: [Malignant pilomatrixoma of head and neck. A case report]. Cancer Radiother; 2010 Jun;14(3):198-201
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pilomatrixoma of head and neck. A case report].
  • [Transliterated title] Le pilomatricome malin cervical métastatique : à propos d'un cas.
  • We report the case of a 66-year-old patient with a pilomatrix carcinoma from the right submandibular region with pulmonary and cerebral metastases.
  • We tried at first a doxorubicine and cisplatine chemotherapy because of the considerable locoregional extension and the existence of pulmonary metastases.
  • The patient response to three cures of chemotherapy was spectacular with a partial clinical response (75%) and a partially cleaned-up chest observed in the radiological evaluation.
  • In the 5th cycle of chemotherapy following the same protocol, the patient presented a relapse with cerebral metastases.
  • The patient received hypofractionated radiotherapy on the brain followed by etoposide and cisplatine chemotherapy, then oral vinorelbine.
  • The patient died of progressive disease after 32 weeks.
  • [MeSH-major] Facial Neoplasms / pathology. Pilomatrixoma / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Pilomatrixoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20434933.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


7. Disayavanish C, Srisurapanont M, Udomratn P, Disayavanish P, Kasantikul D, Netrakom P, Ngamtipwatthana T, Phornchirasilp S, Rangseekajee P, Samuthrsindh P, Sukanich P, Thiam-Kaew K, Visanuyothin T: Guideline for the pharmacotherapy of treatment-resistant schizophrenia. Royal College of Psychiatrists of Thailand. J Med Assoc Thai; 2000 Jun;83(6):579-89
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guideline for the pharmacotherapy of treatment-resistant schizophrenia. Royal College of Psychiatrists of Thailand.
  • The authors proposed to develop an evidence-based guideline relevant to drug use for treatment-resistant schizophrenia (TRS), which will be called "Guideline for the Pharmacotherapy of Treatment-Resistant Schizophrenia or PTRS Guideline".
  • The levels of evidence were graded and recommendations were made by the use of a system modified from that of the AHCPR.
  • Clozapine should be considered as a first-line treatment for TRS.
  • Physicians should use this guideline to accompany others that suggest the overview of treatment for schizophrenia.
  • [MeSH-major] Antipsychotic Agents / administration & dosage. Drug Resistance. Schizophrenia / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Evidence-Based Medicine. Female. Humans. Male. Treatment Failure

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10932483.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Guideline; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] THAILAND
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Number-of-references] 33
  •  go-up   go-down


8. Correale P, Del Vecchio MT, Renieri T, Di Genova G, La Placa M, Remondo C, Savellini GG, Terrosi C, Zurbriggen R, Amacker M, Francini G, Cusi MG: Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. Cancer Lett; 2008 May 18;263(2):291-301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: C-IRIV/PTR-4 is a novel anticancer vaccine construct composed of immune-reconstituted influenza virosomes (IRIV) assembled with the PTH-rP derived peptide (PTR)-4, a synthetic CTL epitope with HLA-A(*)02.01 amino acid binding motifs.
  • MATERIALS AND METHODS: We have investigated the immunological and preventive anti-tumor activity of C-IRIV/PTR-4 compared with the soluble PTR-4 peptide, in HHD mice inoculated with autologous PTH-rP+ tumor cells.
  • RESULTS: Peptide vaccination with either a soluble and an IRIV formulation showed similar immunological activity and the ability to purge the tumor tissue of tumor cell clones able to produce the target antigen (PTR-rP).
  • The most efficient protection from tumor growth was however observed in animals vaccinated with C-IRIV/PTR-4 in which an additional IRIV related anti-angiogenetic effect was detected in the tumor tissue.
  • CONCLUSIONS: These results confirm the immunological activity of PTR-4 vaccination and suggest a more efficacious therapeutic potential of C-IRIV/PTR-4 against bone metastases and malignancies like breast, prostate and lung which very often over-express PTH-rP.
  • [MeSH-major] Cancer Vaccines / pharmacology. Influenza A virus / immunology. Neovascularization, Pathologic / drug therapy. Parathyroid Hormone-Related Protein / administration & dosage. Vaccines, Virosome / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytotoxicity, Immunologic. Humans. Mice. Mice, Transgenic. Vaccines, Subunit / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18291576.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Parathyroid Hormone-Related Protein; 0 / Vaccines, Subunit; 0 / Vaccines, Virosome
  •  go-up   go-down


9. Hennan JK, Swillo RE, Morgan GA, Leik CE, Brooks JM, Shaw GD, Schaub RG, Crandall DL, Vlasuk GP: Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. Thromb Haemost; 2006 Mar;95(3):469-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.
  • GPG-290 (100 microg/kg, n=6; 500 microg/kg, n=6) prolonged time to thrombotic occlusion (TTO) to 105+/-34 and 156+/-23 (p<0.05) min, respectively compared to the saline treated control group (32+/-6 min, n=6).
  • There was an increase in bleeding after the 500 microg/kg dose, but only at the 1 hr time point.
  • Clopidogrel was studied in two dosing regimens representing either a clinical pretreatment regimen (PTR) of 4.3 mg/kg on day -2 followed by 1.1 mg/kg daily for 2 days prior to the procedure or pre-procedural loading dose regimen (LDR) of 4.3 mg/kg 3 hr pre-procedure.
  • The PTR and LDR clopidogrel treatments prolonged TTO to 98.2+/-30.0 min and 136.1+/-39.5 min (p<0.05), and sustained patency in 1/6 and 4/8 vessels, respectively.
  • However, template bleeding time in the LDR clopidogrel group was sustained higher than the control group.
  • The combination of PTR clopidogrel and GPG-290 (100 microg/kg) prolonged TTO equivalent to LDR clopidogrel alone (141.4 +/- 35.1 min) and sustained patency in 3/7 dogs, without increased bleeding while LDR clopidogrel combined with 100 microg/kg GPG-290 prevented occlusion in 5/8 dogs and further prolonged TTO (173.5+/-32.6 min) but was associated with increased bleeding compared to control.
  • [MeSH-minor] Animals. Bleeding Time. Disease Models, Animal. Dogs. Dose-Response Relationship, Drug. Drug Therapy, Combination. Peptides / pharmacology. Platelet Aggregation / drug effects. Platelet Aggregation Inhibitors / pharmacology. Platelet Aggregation Inhibitors / therapeutic use. Recombinant Fusion Proteins / pharmacology. Recombinant Fusion Proteins / therapeutic use. Ticlopidine / analogs & derivatives. Ticlopidine / pharmacology. Ticlopidine / therapeutic use. Time Factors. Vascular Patency / drug effects. von Willebrand Factor / antagonists & inhibitors

  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525575.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Peptides; 0 / Platelet Aggregation Inhibitors; 0 / Platelet Glycoprotein GPIb-IX Complex; 0 / Recombinant Fusion Proteins; 0 / eptifibatide; 0 / glycocalicin; 0 / von Willebrand Factor; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine
  •  go-up   go-down


10. Casner PR, Sandoval E: Increased sensitivity to warfarin in elderly Hispanics. J Clin Pharmacol; 2002 Feb;42(2):145-50
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been suggested that aging enhances the pharmacologic effect of warfarin, but there is little information about the effects of warfarin in aging minority populations.
  • Charts in their anticoagulation clinic were retrospectively examined for the following information: age, sex, weight, duration of anticoagulant therapy, number of medical problems, number of medications, number of minor or major bleeding episodes, prothrombin time, warfarin dose, and international normalized ratio (INR).
  • The dose-adjusted prothrombin time ratio (PTR) and dose-adjusted INR were calculated by dividing the PTR and INR by the mean warfarin dose.
  • Elderly patients had more medical problems (3.1 vs. 2.4) and took more medications (3.4 vs. 2.4) than younger patients.
  • The dose-adjusted PTR and dose-adjusted INR increased with aging (0.59 vs. 0.38 and 0.85 vs. 0.59, p < .05 ANOVA).
  • [MeSH-minor] Data Interpretation, Statistical. Dose-Response Relationship, Drug. Female. Hispanic Americans. Humans. International Normalized Ratio. Male. Middle Aged. Partial Thromboplastin Time. Reference Values. Regression Analysis. Retrospective Studies. Texas

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11831536.001).
  • [ISSN] 0091-2700
  • [Journal-full-title] Journal of clinical pharmacology
  • [ISO-abbreviation] J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 5Q7ZVV76EI / Warfarin
  •  go-up   go-down


11. Klein RL, Hirko AC, Meyers CA, Grimes JR, Muzyczka N, Meyer EM: NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res; 2000 Sep 1;875(1-2):144-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rats received intraseptal injections of either the control vector, pTR-UF4, or the pTR-NGFmyc at 3 months of age, prior to testing their performance in the Morris water task.
  • An age-related decrease in the acquisition of the hidden platform location was found at 12 months of age in the pTR-UF4 control group, but not in the pTR-NGFmyc group.
  • Further, when compared to 3 month old untreated animals, the control group, but not the pTR-NGFmyc group, was impaired at 12 months of age.
  • This approach may therefore represent a viable therapy for age-related dementia involving dysfunction in cholinergic activity and memory, such as Alzheimer's disease.
  • [MeSH-major] Aging / psychology. Memory Disorders / prevention & control. Nerve Growth Factor / pharmacology. Neurons / drug effects. Prosencephalon / drug effects. Space Perception / physiology
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Behavior, Animal / physiology. Cell Size. Choline O-Acetyltransferase / metabolism. Gene Expression. Gene Transfer Techniques. Male. Memory / physiology. Rats. Rats, Sprague-Dawley. Transgenes / physiology

  • MedlinePlus Health Information. consumer health - Memory.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10967308.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / P01 AG 10485; United States / NINDS NIH HHS / NS / P01 NS 36302
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9061-61-4 / Nerve Growth Factor; EC 2.3.1.6 / Choline O-Acetyltransferase
  •  go-up   go-down


12. Ionta MT, Scanu A, Atzori F, Vacca D, Contu A, Farris A, Lorusso V, Palmeri S, Minerba L, Massidda B: Unexpectedly high survival rate in very poor prognosis stage III B breast cancer patients receiving cisplatin-based primary chemotherapy. A multicenter Italian study. J Clin Oncol; 2004 Jul 15;22(14_suppl):605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpectedly high survival rate in very poor prognosis stage III B breast cancer patients receiving cisplatin-based primary chemotherapy. A multicenter Italian study.
  • : 605 Background: Primary chemotherapy, as part of multimodality treatment, has become the standard of care for locally advanced breast cancer (LABC) to increase DFS, OS and conservative surgery.
  • Stage III B is renowned as the worst of LABC, and despite appropriate therapy the majority of patients (pts) will experience distant metastases and death within 2-3 years.
  • The optimal regimen and schedule of primary chemotherapy is uncertain.
  • METHODS: Between 1996 and 2001 72 consecutive III B pts were treated with primary chemotherapy: Cisplatin 50 mg/m2, Epirubicin 100 mg/m2, Vinorelbine 25 mg/m2 every 14 (44%) or 21 (66%) days for 4 (33%) or 6 (67%) cycles, followed by surgery, radiation, adjuvant CMF 1, 8 q28 x 6 cycles + - TAM.
  • RESULTS: All patients underwent surgery ( 25% conservative); according to Sataloff's classification 28% had pCR (absence or minimal microscopic residual disease) and 72% had pTR (gross residual disease) in breast; 40% had complete clearance of axilla (pN0) and 60% had residual nodes metastases (pN+); 22% had pCR both in breast and axilla.
  • At median follow up of 52 months (22-87) DFS and OS were 64% and 76% respectively, significantly higher in pCR(85%and 95%) (p= 0.02) and in pN0 (83%and 90%) (p= 0.01) than in pTR(56%and 69%) or in pN+(51%and 67%).
  • CONCLUSIONS: Primary PEV regimen, as part of multimodality treatment, appears to be highly active in terms of pCR, conservative surgery and survival rates in IIIB breast cancer patients and cost-effective.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016634.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Miki H, Ozaki S, Tanaka O, Lee E, Takimoto T, Watanabe H, Fujii S, Nakamura S, Kagawa K, Takeuchi K, Yata K, Abe M, Kagami S, Matsumoto T: Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma. Int J Hematol; 2009 Mar;89(2):223-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.
  • We report a patient with refractory multiple myeloma (MM) who developed platelet transfusion refractoriness (PTR).
  • She underwent high-dose chemotherapy followed by autologous stem cell transplantation, and achieved a very good partial response.
  • Therefore, she was considered to have developed PTR due to anti-HLA class I antibody caused by the previous blood transfusions.
  • In addition, platelet transfusion from random donors showed clinical effects after BD therapy.
  • This case suggests that bortezomib might be effective in different types of immune disease by inhibiting allo-reactive antibody.
  • [MeSH-major] Boronic Acids / therapeutic use. Multiple Myeloma / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Antibodies. Bortezomib. Dexamethasone / therapeutic use. Female. HLA Antigens / immunology. Hematopoietic Stem Cell Transplantation. Humans. Middle Aged. Platelet Transfusion. Salvage Therapy. Transplantation, Homologous

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2005 Jun;129(6):776-83 [15953004.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1783-92 [17308121.001]
  • [Cites] N Engl J Med. 2004 Oct 28;351(18):1860-73 [15509819.001]
  • [Cites] Int J Hematol. 2007 Aug;86(2):180-5 [17875535.001]
  • [Cites] Haematologica. 2005 Feb;90(2):247-53 [15710579.001]
  • [Cites] Blood. 2004 Jan 1;103(1):20-32 [12969978.001]
  • [Cites] Blood. 2006 Jul 15;108(2):551-8 [16537813.001]
  • [Cites] Leukemia. 2007 Jan;21(1):30-6 [17096016.001]
  • [Cites] Nat Med. 2008 Jul;14(7):748-55 [18542049.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • (PMID = 19225725.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / Boronic Acids; 0 / HLA Antigens; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


14. Mirkovic T, Paver-Erzen V, Klokocovnik T, Gursahaney A, Hernandez P, Gottfried SB: Tracheal pressure regulated volume assist ventilation in acute respiratory failure. Can J Anaesth; 2007 Jun;54(6):420-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was hypothesized that regulating tracheal (Ptr) rather than airway opening pressure (Pao), to overcome endotracheal tube related resistive effort, during VAV would provide an effective alternative method of ventilation.
  • We therefore compared the effects of Pao and Ptr regulated VAV on breathing pattern and inspiratory effort.
  • METHODS: In seven intubated patients, flow, volume, Pao, Ptr, esophageal and transdiaphragmatic pressure were measured during VAV (0-80% respiratory system elastance) using Pao vs Ptr to regulate ventilator applied pressure.
  • Breathing pattern and the pressure-time integral of the inspiratory muscles (integralP(mus) .
  • dt) and diaphragm (integralP(di) .
  • dt) were determined.
  • dt = 39.6 +/- 7.5 vs 28.5 +/- 7.2 cm H(2)O.sec.L(-1), integralP(di) .
  • dt, = 35.4 +/- 7.8 vs 24.2 +/- 5.9 cm H(2)O.sec.L(-1), VAV 0 vs 80%; P < 0.05) due to a decrease in elastic related effort.
  • dt, and integralP(di) .
  • dt (which averaged 23.6 +/- 2.7, 33.7 +/- 4.4, and 38.5 +/- 5.1%, respectively; P < 0.05) for Ptr compared to Pao regulated VAV due to a decrease in resistive effort.
  • [MeSH-major] Respiration, Artificial. Respiratory Insufficiency / therapy. Trachea / physiology
  • [MeSH-minor] Acute Disease. Aged. Data Interpretation, Statistical. Diaphragm / physiopathology. Female. Humans. Intubation, Intratracheal. Male. Middle Aged. Oxygen / blood. Positive-Pressure Respiration. Pressure. Respiratory Mechanics / physiology. Respiratory Muscles / physiopathology. Tidal Volume / physiology. Transducers

  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can J Anaesth. 2007 Jun;54(6):407-13 [17541068.001]
  • (PMID = 17541070.001).
  • [ISSN] 0832-610X
  • [Journal-full-title] Canadian journal of anaesthesia = Journal canadien d'anesthésie
  • [ISO-abbreviation] Can J Anaesth
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


15. Oswiecimska JM, Ziora KT, Ziora KN, Pindycka-Piaszczynska M, Zajecki W, Pikiewicz-Koch A, Stojewska M: Growth hormone therapy in boy with panhypopituitarism may induce pilomatricoma recurrence: case report. Neuro Endocrinol Lett; 2008 Feb;29(1):51-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone therapy in boy with panhypopituitarism may induce pilomatricoma recurrence: case report.
  • Pilomatricoma is usually a solitary subcutaneous nodule.
  • Pilomatricoma occurrence in patients with growth hormone (GH) deficiency has not been reported, yet.
  • We report a 14-year-old boy with pilomatricoma and panhypopituitarism.
  • After GH therapy had been started, we observed two relapses of previously completely excised pilomatricoma in the same location and a new pilomatricoma formation on the chin.
  • [MeSH-major] Growth Hormone / adverse effects. Growth Hormone / therapeutic use. Hair Diseases / chemically induced. Hypopituitarism / drug therapy. Neoplasm Recurrence, Local / chemically induced. Pilomatrixoma / chemically induced. Skin Neoplasms / chemically induced
  • [MeSH-minor] Adolescent. Dose-Response Relationship, Drug. Humans. Insulin-Like Growth Factor I / metabolism. Male

  • Genetic Alliance. consumer health - Pituitary hormone deficiency, combined 2.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283258.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


16. Kim ES, Kim KJ, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK: Metaplastic ossification in a cutaneous pyogenic granuloma: a case report. J Dermatol; 2004 Apr;31(4):326-9
Hazardous Substances Data Bank. TRICHLOROACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous ossification may occur in association with a variety of cutaneous neoplasms and inflammatory conditions, such as pilomatricomas, basal cell carcinomas, nevi, chondroid syringomas, venous stasis, and scars.
  • However, it has rarely been reported in pyogenic granuloma, a relatively common benign vascular tumor of the skin and mucous membranes.
  • We herein presented a rare case of cutaneous pyogenic granuloma with ectopic ossification on the big toe of a 37-year-old man, with high recurrence despite repeated CO2 laser ablations.
  • [MeSH-major] Granuloma, Pyogenic / diagnosis. Neoplasm Recurrence, Local / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Caustics / administration & dosage. Diagnosis, Differential. Drug Administration Schedule. Humans. Laser Therapy. Male. Ossification, Heterotopic / diagnosis. Ossification, Heterotopic / drug therapy. Ossification, Heterotopic / pathology. Ossification, Heterotopic / surgery. Toes. Trichloroacetic Acid / administration & dosage

  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15187328.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Caustics; 5V2JDO056X / Trichloroacetic Acid
  •  go-up   go-down


17. Corti MA, Mainetti C: Methylaminolevulinic acid-based photodynamic therapy: the patient's view. Photomed Laser Surg; 2010 Oct;28(5):697-702
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylaminolevulinic acid-based photodynamic therapy: the patient's view.
  • Topical photodynamic therapy (PDT) with methylaminolevulinate (MAL) for nonmelanomatous skin cancers (NMSC) has proven efficient and safe.
  • Because pain and a phototoxic reaction (PTR) are frequent side effects, the ability to predict discomfort may improve the management of patient care.
  • During a 3-month period, we enrolled 46 patients with a total of 120 precancerous actinic skin lesions or NMSCs.
  • With approximately 80% of the lesions, the patient reported light or no PTR.
  • Risk factors for a greater severity of pain were lesions on the scalp (average pain score: 6.62) and on the forehead (average: 7.00) and treatment over an extended area (average: 7.32).
  • Treatment on the nose (average: 3.29) or on the thorax (average: 3.00) was less painful.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Pain Measurement / drug effects. Photochemotherapy / methods. Precancerous Conditions / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Female. Follow-Up Studies. Humans. Male. Middle Aged. Patient Satisfaction. Photosensitizing Agents / therapeutic use. Prospective Studies. Risk Assessment. Statistics, Nonparametric. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20961234.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down






Advertisement